ERBB2 and breast carcinoma: While some studies suggest that overexpression of IGF-IR or phosphorylated IGF-IR is inversely associated with patient prognosis among all subtypes of breast cancer [36–38], another study reveals that IGF-IR is only inversely associated with prognosis in ErbB2-positive breast cancer [39].